Oncology Clinical Trial
— PREFEROfficial title:
Assessment of ONS-flavour Preference in Cancer Patients With and Without Taste Alterations
Verified date | August 2023 |
Source | Nutricia Research |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A single arm intervention study examining ONS-flavour preference in cancer patients with and without taste alterations
Status | Completed |
Enrollment | 64 |
Est. completion date | March 28, 2023 |
Est. primary completion date | March 28, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Being diagnosed with cancer 2. Undergoing, or having undergone systemic anti-cancer treatment or radiotherapy in the past 12 months. 3. Age > 18 years 4. Written informed consent Exclusion Criteria: 1. Taste and smell alterations not caused by the cancer or anti-cancer treatment 2. Galactosaemia 3. Use of thickener to be able to swallow safely 4. Allergies to any of the product ingredients or any of the flavours 5. Current prescription for ONS, enteral nutrition or parenteral nutrition 6. Diabetes mellitus Type I or Type II 7. Open sores or severe inflammation in the mouth or throat 8. Undergoing dialysis 9. Hepatic encephalopathy 10. Patients with heart failure who have symptoms of heart failure at rest and/or are unable to carry on any physical activity without discomfort 11. Known pregnancy or lactation 12. Average alcohol use of > 21 glasses per week for men or > 14 glasses per week for women or drug abuse in opinion of the investigator 13. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements 14. Participation in any other studies involving food products concomitantly or within two weeks prior to entry into the study. 15. Employees of Nutricia Research and/or partners, parents, children and brothers/sisters of employees |
Country | Name | City | State |
---|---|---|---|
Netherlands | Nutricia Clinical Research Unit | Utrecht |
Lead Sponsor | Collaborator |
---|---|
Nutricia Research |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Choice for the Fortimel/Nutridrink Compact Protein sensation flavour over the Fortimel/Nutridrink Compact Protein regular flavour | Subjects take one sensation flavour and one regular flavour and are asked in a direct question which flavour they prefer. | On 4 days | |
Secondary | Difference between average liking scores [score 0-10] for Fortimel/Nutridrink Compact Protein sensation flavour range versus Fortimel/Nutridrink Compact Protein regular flavour range | On 4 days | ||
Secondary | Choice for the Fortimel/Nutridrink Compact Protein sensation flavours over the Fortimel/Nutridrink Compact Protein regular flavours between patients with and patients without Taste and Smell Alterations | Subjects take one sensation flavour and one regular flavour and are asked in a direct question which flavour they prefer. | On 4 days | |
Secondary | Difference in average liking scores [score 0-10] for Fortimel/Nutridrink Compact Protein sensation flavour versus Fortimel/Nutridrink Compact Protein regular flavour between patients with and patients without Taste and Smell Alterations | On 4 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01439152 -
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Active, not recruiting |
NCT06015009 -
Symptom Management App for Children at the Early Stage of Cancer Survivorship and Their Caregivers
|
N/A | |
Active, not recruiting |
NCT03298100 -
Risk Scoring Model for Endometrial Cancer
|
||
Recruiting |
NCT05055609 -
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT04324320 -
Psychological Distress in Outpatient Oncological Rehabilitation
|
||
Completed |
NCT00588289 -
Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA
|
N/A | |
Recruiting |
NCT06222801 -
The 1st Tumor CytokinoTherapy Database (TCTD-1)
|
||
Recruiting |
NCT03831633 -
Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients
|
Phase 4 | |
Completed |
NCT04914702 -
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
|
||
Recruiting |
NCT05198570 -
Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
|
||
Recruiting |
NCT05712174 -
A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT03832062 -
Value of Analysing Under-utilised Leftover Tissue (VauLT)
|
||
Completed |
NCT03988777 -
Magnetic Seed Localisation for Nonpalpable Breast Lesions
|
||
Recruiting |
NCT06031233 -
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
|
Phase 4 | |
Enrolling by invitation |
NCT04019119 -
Digital Intervention for the Modification of Lifestyles (iGame)
|
N/A | |
Not yet recruiting |
NCT05926362 -
Capillary-Venous Paired Data Collection
|
||
Recruiting |
NCT05686213 -
ExeNTrO: Exercise During Neoadjuvant Chemoradiation Treatment to Improve Rectal and Esophageal Cancer Outcome - Pilot Trial
|
Phase 2 | |
Recruiting |
NCT05510856 -
Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients
|
Phase 4 | |
Completed |
NCT04180306 -
PEWS Implementation in an LMIC Setting
|
N/A |